Evelo Biosciences Inc expected to post a loss of $3.30 a share - Earnings Preview

Evelo Biosciences

07/08/2023 19:34

* Evelo Biosciences Inc  EVLO.OQ   EVLO.O  is expected
to show no
change in quarterly revenue when it reports  results on August 9
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Evelo Biosciences
Inc is
for a loss of $3.30 per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $15​, above​ its last closing price of $9.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -3.24       -3.16      -4.60     Missed  -45.6
 Dec. 31 2023  -5.45       -5.52      -4.20     Beat    23.9
 Sep. 30 2022  -6.96       -6.70      -5.60     Beat    16.4​
 Jun. 30 2022  -8.83       -8.67      -8.00     Beat    7.7
 ​​Mar.        -11.54      -11.64     -11.20    Beat    3.8
 31 2022                                                
 Dec. 31 2021              -12.20     -10.80    Beat    11.5​
 Sep. 30 2021  -11.06      -10.80     -12.60    Missed  -16.7
 Jun. 30 2021  -10.67      -10.83     -10.60    Beat    2.2
 This summary was machine generated August 7 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated